Trabectedin

Introduction Overview

Generic Name

trabectedin

Brand Name

Yondelis

Dosage Form

Intravenous infusion

Drug Class

Alkylating agents

Pharmacokinetics

Absorption:
Trabectedin is administered intravenously, bypassing the gastrointestinal tract, so absorption mechanisms typical of oral drugs do not apply. This intravenous route ensures complete bioavailability, allowing immediate therapeutic plasma concentrations. The prolonged infusion (up to 24 hours) facilitates controlled plasma exposure, optimizing efficacy and limiting peak-related toxicity. Clinical pharmacokinetic studies highlight that trabectedin plasma concentrations reach steady state during prolonged infusion, with rapid attainment of effective therapeutic levels while minimizing acute adverse effects.

Distribution:
Trabectedin exhibits extensive tissue distribution due to its lipophilic nature and high affinity for DNA in malignant cells. Plasma protein binding of trabectedin is moderate to high, influencing its pharmacodynamic profile. The volume of distribution (Vd) is substantial, reflecting accumulation in tumor and various normal tissues. Studies indicate that trabectedin binds to DNA in connective and fatty tissues, relevant for its activity in liposarcoma and leiomyosarcoma. The drug crosses into tissues such as muscle, fat, and vascular structures where sarcomas originate. Distribution is modulated by factors such as plasma albumin levels and tumor vascularization.

Metabolism:
Trabectedin undergoes extensive hepatic metabolism, primarily via cytochrome P450 enzymes, notably CYP3A4 isoenzyme. Metabolic biotransformation involves oxidative pathways generating metabolites with limited cytotoxic activity. The hepatic microsomal system's role is significant, suggesting that concomitant medications that inhibit or induce CYP3A4 have notable implications for trabectedin plasma levels and toxicity. Metabolism also reflects phase II conjugation processes, yet oxidative metabolism predominates. Preclinical and clinical data suggest that variations in hepatic function markedly influence trabectedin clearance and systemic exposure, necessitating dose adjustments in hepatic impairment.

Elimination:
Elimination of trabectedin and its metabolites occurs predominantly via biliary excretion into the feces, with minor renal clearance. Approximately 70-80% of administered drug-related material is excreted in feces within several days post-infusion, with less than 10% recovered unchanged in urine. Trabectedin’s elimination half-life is long, ranging approximately 30 to 180 hours depending on patient factors and dosing regimen. Its clearance shows variability influenced by hepatic function, underscoring close monitoring during therapy. The drug is eliminated slowly, necessitating dosing intervals of typically three weeks to allow recovery from toxicities such as myelosuppression and hepatotoxicity.

Dosage Forms

Available Dosage Forms:
- Intravenous infusion solution supplied as vials for reconstitution

Dosages for Adults and Adolescents:
- Recommended dose: 1.5 mg/m2 administered as a 24-hour intravenous infusion every 21 days (once every 3 weeks). Treatment continues until disease progression or unacceptable toxicity.

Specific Patient Populations:
- Patients with normal bilirubin and AST or ALT levels ≤ 2.5 times the upper limit of normal (ULN) are eligible for standard dosing.
- For patients with serum bilirubin levels above institutional ULN, use of Yondelis is not recommended due to increased risk of toxicity.
- Dose adjustments may be necessary based on hepatic function, hematologic parameters, and adverse reaction profiles.

Administration Notes:
- Infusion should be given via a central venous line using an infusion set with 0.2 micron polyethersulfone (PES) in-line filter.
- Complete the infusion within 30 hours of drug reconstitution.
- Premedication with dexamethasone 20 mg IV 30 minutes prior to trabectedin infusion is required to reduce liver toxicity and infusion-related reactions.
- Careful monitoring of liver function tests, hematologic parameters, and cardiac function (ECG) is mandatory throughout treatment.

Mechanism Of Action

Trabectedin is a unique alkylating agent originally derived from the marine tunicate Ecteinascidia turbinata, which exerts its antineoplastic effects primarily by binding to the minor groove of DNA. At a molecular level, trabectedin forms covalent bonds predominantly with guanine residues in specific nucleotide triplets, causing a bend in the DNA helix toward the major groove. This conformational distortion interferes with the transcription machinery, inhibiting RNA polymerase II progression, and effectively halts transcription-coupled nucleotide excision repair (TC-NER).

Cellularly, this leads to the preferential accumulation of DNA breaks and apoptosis in tumor cells with active transcription. By trapping transcription-coupled repair proteins, trabectedin induces a cascade of events culminating in double-strand DNA breaks, ultimately triggering programmed cell death. Additionally, trabectedin affects the tumor microenvironment by modulating the activity of tumor-associated macrophages, reducing pro-inflammatory cytokines, and impairing their support to cancer growth and metastasis.

Biochemically, trabectedin’s activity is distinct from classical alkylators such as cyclophosphamide or nitrogen mustards, as its binding pattern and interference in transcription-coupled repair give it a targeted cytotoxic profile, especially effective in sarcomas like liposarcoma and leiomyosarcoma. Clinical relevance stems from these mechanisms by which trabectedin overcomes resistance to other agents targeting DNA replication.

Research evidence from Phase II and III clinical trials supports trabectedin’s unique mechanism, demonstrating significant improvement in progression-free survival in patients with advanced soft tissue sarcomas refractory to standard chemotherapies. Studies also suggest its immunomodulatory effects enhance antitumor activity, potentially synergizing with other therapeutic modalities under investigation.

Pharmacological Actions

Alkylating agent that covalently binds to guanine residues in DNA minor groove.
Inhibits transcription-coupled nucleotide excision repair, disrupting RNA polymerase II function.
Induces DNA helix bending leading to DNA strand breaks and apoptosis.
Modulates tumor microenvironment by altering tumor-associated macrophage activity.
Exerts selective cytotoxicity against liposarcoma and leiomyosarcoma cells.
Inhibits proliferation of malignant cells through transcription inhibition.
Exhibits anti-inflammatory effects by downregulating pro-inflammatory cytokines within tumor surroundings.
Demonstrates immunomodulatory properties potentially enhancing host antitumor immunity.
Interferes with DNA repair mechanisms enhancing cytotoxic effects in resistant cancer cells.
Displays prolonged plasma half-life contributing to sustained antitumor activity.

Therapeutic Or Clinical Uses

Treatment of unresectable or metastatic liposarcoma.
Therapy for unresectable or metastatic leiomyosarcoma.
Used in patients who have received prior anthracycline-containing chemotherapy regimens.
Management of advanced soft tissue sarcomas refractory to standard treatments.
Indicated for cancers originating in fatty tissue, muscle, bone, joints, and blood vessels.
Utilized to control disease progression in sarcomas with metastatic spread.
Option for patients ineligible for surgical intervention due to tumor extent.
Part of second-line or subsequent line therapy for soft tissue sarcoma.
Facilitates tumor burden reduction and symptomatic improvement.
Incorporated into combinations in investigational protocols for enhanced efficacy.

Side Or Adverse Effects

Myelosuppression including neutropenia, anemia, and thrombocytopenia leading to increased infection risk.
Hepatotoxicity manifested by elevations in liver transaminases (AST, ALT) and bilirubin abnormalities.
Nausea, vomiting, and gastrointestinal disturbances such as diarrhea and constipation.
Infusion site reactions including pain, burning, irritation, and local skin changes.
Fatigue and generalized weakness frequently observed in treated patients.
Headache and central nervous system symptoms including dizziness and confusion.
Capillary leak syndrome characterized by sudden peripheral edema, hypotension, and respiratory distress.
Cardiac effects including chest pain, palpitations, dyspnea, and signs of heart failure.
Musculoskeletal toxicity with muscle pain, tenderness, and rhabdomyolysis features including dark urine.
Allergic reactions ranging from mild rash and urticaria to severe anaphylaxis.
Increased susceptibility to infections due to immune suppression.
Elevated serum creatinine and renal function abnormalities indicating nephrotoxicity.
Respiratory side effects including shortness of breath and cough.
Electrolyte disturbances secondary to gastrointestinal loss or organ dysfunction.
Potential for treatment delay or discontinuation due to intolerable toxicity.

Precautions

Closely monitor liver function tests prior to each dose due to risk of hepatotoxicity.
Consider baseline and periodic cardiac function assessment using ECG or echocardiography.
Perform routine complete blood counts to detect myelosuppression and prevent severe infections.
Avoid use in patients with elevated bilirubin levels above institutional normal limits.
Use caution in patients with pre-existing liver, kidney, or heart disease.
Ensure adequate hydration and supportive care to minimize nephrotoxicity.
Premedicate with corticosteroids (e.g., dexamethasone) to reduce risk of liver toxicity and infusion reactions.
Instruct patients and caregivers on proper handling and disposal of body fluids to prevent exposure.
Recommend effective contraception for men and women during treatment and for months following therapy.
Advise against breastfeeding during treatment due to potential drug transmission.
Monitor for signs and symptoms of capillary leak syndrome and intervene promptly.
Take precautions to avoid infections, including timely vaccination and prompt treatment of febrile episodes.
Avoid grapefruit and grapefruit-containing products that can interfere with metabolism.
Use central venous access for drug administration to reduce infusion-related complications.
Adjust dosing schedules in response to adverse effects or laboratory abnormalities.

Warnings

Severe myelosuppression with risk of fatal infections; monitor blood counts regularly.
Potential for serious hepatotoxicity including liver failure; monitor hepatic function closely.
Risk of capillary leak syndrome, a rare but life-threatening condition requiring immediate medical attention.
Contraindicated in patients with hypersensitivity to trabectedin or any component of the formulation.
May cause fetal harm; strict contraception is required during and after treatment.
Increased susceptibility to infections due to immunosuppressive effects.
Possible cardiac adverse events including arrhythmias and congestive heart failure.
Careful monitoring essential to prevent and manage infusion-related reactions.
Delayed recovery of blood cell counts may necessitate treatment interruption or dose reduction.
Drug accumulation in hepatic impairment may lead to increased toxicity; use is not recommended in severe liver dysfunction.
Avoid concomitant use with strong CYP3A4 inhibitors or inducers without adequate monitoring.
Immediate discontinuation advised if severe allergic reaction occurs.
Strict adherence to infusion protocols required to minimize local and systemic toxicity.
Handling precautions due to excretion of active drug in body fluids posing exposure risk to caregivers.
Use in pregnancy or lactation is contraindicated due to teratogenic potential.

Contraindication

Known hypersensitivity or allergy to trabectedin.
Patients with serum bilirubin levels above institutional upper limit of normal.
Severe hepatic impairment or active liver disease.
Pregnancy due to teratogenicity and potential fetal harm.
Breastfeeding during treatment.
Patients with pre-existing severe cardiac disease without careful monitoring.
Concurrent use of potent CYP3A4 inhibitors or inducers without adjustment.
Active uncontrolled infections or sepsis at the time of treatment initiation.
Patients with significant hematologic abnormalities (severe neutropenia or thrombocytopenia) before dosing.
Known hypersensitivity to equivalent excipients used in infusion preparation.
Uncontrolled severe gastrointestinal disorders compromising drug administration.
Inadequate venous access preventing safe intravenous administration.
Individuals unable or unwilling to comply with monitoring and contraception recommendations.
History of severe capillary leak syndrome related to prior therapies.
Patients with HIV on antiretroviral therapies that interact strongly with CYP3A4 enzymes without supervision.

Drug Interactions

Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) can increase trabectedin plasma levels, enhancing toxicity risk.
CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce trabectedin efficacy by increasing metabolism.
Concomitant use with hepatotoxic drugs may exacerbate liver injury.
Drugs causing myelosuppression (e.g., other chemotherapeutics) can increase hematologic toxicity when combined.
Use with dexamethasone is recommended to mitigate hepatic and infusion-related side effects.
Grapefruit and grapefruit juice can inhibit CYP3A4 and increase trabectedin concentrations.
Potential interaction with anticoagulants warrants monitoring coagulation parameters.
Concurrent administration with P-glycoprotein modulators could alter trabectedin pharmacokinetics.
Co-administration with immunosuppressants may increase risk of infections.
Potential interference with medications affecting cardiac conduction or function.
Synergistic toxicity may occur with nephrotoxic agents requiring renal function monitoring.
Avoid alcohol consumption that may augment hepatotoxicity.
Interaction with herbal supplements metabolized by CYP3A4, such as St. John's Wort, can affect drug levels.
Concomitant use of antiemetics to manage nausea and vomiting is common and requires attention to additive side effects.
Careful review of all prescription and over-the-counter meds advised before initiating treatment.

Preparations Of The Drug

Trabectedin is supplied as a sterile lyophilized powder for intravenous infusion.
Reconstituted solution is prepared under aseptic conditions using specific diluents.
The infusion solution requires a 0.2 micron polyethersulfone (PES) in-line filter during administration.
Stable for use if the complete infusion is administered within 30 hours of preparation.
Administered exclusively via central venous catheter over 24 hours to optimize pharmacodynamics and safety.
Premedication with dexamethasone 20 mg IV 30 minutes prior to infusion standard to reduce adverse effects.
Packaging includes protective materials to maintain stability and prevent contamination.
Storage conditions require refrigeration and protection from light before reconstitution.
Handling requires strict adherence to cytotoxic drug safety protocols to protect healthcare personnel.
Used under supervision in specialized oncology settings trained in administration of chemotherapy agents.
Instructions include guidelines for disposal of hazardous waste and contaminated materials.
Accompanied by detailed prescribing information with dosing protocols and safety monitoring recommendations.
Contains no agents for oral administration; not formulated for subcutaneous or intramuscular routes.
Multiple vial sizes available to tailor dosing according to patient body surface area calculations.
Preparation and administration require coordination with pharmacy and nursing staff for optimized patient care.